Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31070819, 31270984)
- Special Fund of Chongqing Key Laboratory (CSTC)
- Foundation of National Key Discipline in Laboratory Medicine (2010302)
- Scientific and Technological Research Program of Chongqing Municipal Education Commission (KJ120318)
This publication has 49 references indexed in Scilit:
- Nanogel-Based PspA Intranasal Vaccine Prevents Invasive Disease and Nasal Colonization by Streptococcus pneumoniaeInfection and Immunity, 2013
- Novel Protein-Based Pneumococcal Vaccines Administered with the Th1-Promoting Adjuvant IC31 Induce Protective Immunity against Pneumococcal Disease in Neonatal MiceInfection and Immunity, 2012
- A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptorsVaccine, 2011
- TLR-based immune adjuvantsVaccine, 2011
- TH17-Based Vaccine Design for Prevention of Streptococcus pneumoniae ColonizationCell Host & Microbe, 2011
- Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in RabbitsPLOS ONE, 2011
- Mast cell-orchestrated immunity to pathogensNature Reviews Immunology, 2010
- Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthraxProceedings of the National Academy of Sciences, 2010
- Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimatesThe Lancet, 2009
- The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigenVaccine, 2009